Applying Evidence-Based Strategies to Improve Outcomes in HER2-Negative Early Breast Cancer

Download the slides, read the commentary, and view an on-demand webcast to gain expert insights on the implementation of targeted therapy and immunotherapy into (neo)adjuvant treatment regimens for patients with HER2-negative early breast cancer.

Share

Program Content

Activities

HER2 Negative EBC
Applying Evidence-Based Strategies to Improve Outcomes in HER2-Negative Early Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 29, 2024

Expires: April 28, 2025

Activities

HER2-negative early breast cancer
Key Takeaways in the Management of HER2-Negative Early Breast Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 08, 2024

Expires: May 07, 2025

HER2-Negative EBC With gBRCA PV
Key Takeaways in the Management of HER2-Negative Early Breast Cancer: Focus on Treating Patients With Pathogenic Variants in Germline BRCA
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 17, 2024

Expires: May 16, 2025

Activities

HER2neg EBC
Applying Evidence-Based Strategies to Improve Outcomes in HER2-Negative Early Breast Cancer
Video
Congratulations: You achieved a completion on 04/09/2022

Released: May 21, 2024

Expires: May 20, 2025

Faculty

cover img faculity

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
UK Healthcare
Lexington, Kentucky

cover img faculity

Jordan Hill, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
West Virginia University Cancer Institute
Morgantown, West Virginia

Provided by

ProCE Banner

Provided by ProCE, LLC, in partnership with Clinical Care Options

Supporters

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.

AstraZeneca

Merck Sharp & Dohme, LLC

Partners

Clinical Care Options, LLC

ProCE Banner